Arsenic trioxide: Its role in acute promyelocytic leukemia and potential in other hematologic malignancies

Blood Reviews

Volumn 15, Issue 3, 2001, Pages 133-142

  Tallman, M S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; ARSENIC TRIOXIDE; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

BLOOD DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPERGLYCEMIA; LEUKOCYTOSIS; NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT INTERVAL; RELAPSE; REVIEW; SKIN MANIFESTATION; SURVIVAL TIME; VERTIGO; WEIGHT GAIN;

EID: 0034783139     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0160     Document Type: Article

References (105)

1. Heavy metals and heavy metal antagonists
2. Arsenic as a therapeutic agent in chronic myeloid leukemia
3. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia
4. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine
5. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
6. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
7. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
8. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
9. Deconstructing a disease: RARα, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia
10. Acute promyelocytic leukemia: Results of treatment by daunorubicin
11. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses
12. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia
13. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
14. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
15. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
16. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines
17. Arsenic-induced apoptosis in malignant cells in vitro
18. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
19. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of bcl-2 protein
20. A caspace-activated DNAse that degrades DNA during apoptosis, and its inhibitor ICAD
21. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
22. All-trans-retinoic acid in acute promyelocytic leukemia
23. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
24. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
25. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
26. A modified AIDA protocol with anthracycline efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia
27. Double induction strategy including high-dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia
28. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group
29. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report
30. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA Cooperative groups
31. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
32. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome results and prognostic factor analysis from Intergroup protocol 0129
33. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan. A high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment
34. The JALSG APL92 Study for newly diagnosed acute promyelocytic leukemia (APL) Analysis of prognostic factors to increase cure rate in the next study
35. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
36. Prevalence and prognostic significance of FIt3 internal tandem duplication in pediatric acute myeloid leukemia
37. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study
38. Secondary cytogenetic changes in acute promyelocytic leukemia-prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B study
39. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
40. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
41. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
42. Immunophenotype of adult and childhood acute promyelocytic leukemia: Correlation with morphology, type of PML and clinical outcome. A cooperative Italian study on 196 cases
43. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA
44. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
45. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
46. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia
47. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial
48. Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia
49. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
50. Molecular remission induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
51. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid
52. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: Clinical experience with a new synthetic retinoid Am-80
53. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) cases apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases
54. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene
55. European survey of bone marrow transplantation in acute promyelocytic leukemia
56. The role of stem cell transplantation in acute promyelocytic leukemia
57. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia: II. Clinical efficacy and pharmacokinetics in relapsed patients
58. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
59. Arsenic trioxide in relapsed acute promyelocytic leukemia: The combine results and follow-up from the US pilot and multicenter trials
60. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells
61. In vitro studies on cellular and molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leukemia: Arsenic trioxide induces NB4 cell apoptosis with downregulation of bcl-2 expression and modulation of PML-RARα/PML proteins
62. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells
63. Role of SUMO-1-modified PML in nuclear body formation
64. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells
65. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore
66. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
67. Protease to die for
68. The US multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
69. Studies of treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
70. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD 13 expression in patients treated with all-trans retinoic acid
71. Incidence, clinical features, and outcome of all-trans retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
72. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
73. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
74. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
75. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide
76. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
77. Arsenic trioxide (ATO): Analysis of the QT prolongation on electrocardiogram (ECG)
78. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage
79. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
80. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
81. Arsenic compounds induces apoptosis in multiple myeloma (MM): Role of NFKb-RIP pathway
82. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines
83. The effects of arsenic trioxide on human megakaryocytic leukemia cell lines
84. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express bcr-abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL
85. Transcription: Gene control by targeted histone acetylation
86. Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid
87. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
88. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic
89. Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells
90. Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells
91. Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione
92. Reactions of arsenic(III) and arsenic(V) species with glutathione
93. Enhanced cytotoxicity to arsenic trioxide in resistant multiple myeloma by butathione sulfoxime (BSO)
94. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?
95. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
96. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells
97. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids
98. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells
99. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells
100. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
101. Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)
102. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
103. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukemia cells with t(11;17) in combination with all-trans retinoic acid
104. 3) ±all-trans retinoic acid (ATRA): The French As98 Study
105. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia